Compound 33 is a novel K(ATP) opener that demonstrates cardioprotective and neuroprotective effects in preclinical models without vasorelaxation.
No takes yet. Share an insight, caveat, or question.
Supports preclinical development of cardioselective K(ATP) openers for myocardial protection; human translation remains untested.
Yoo et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: